X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2136) 2136
Book Review (756) 756
Publication (120) 120
Book Chapter (8) 8
Conference Proceeding (5) 5
Magazine Article (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1884) 1884
humans (1862) 1862
diabetes mellitus, type 2 - drug therapy (1396) 1396
dipeptidyl-peptidase iv inhibitors - therapeutic use (1098) 1098
male (910) 910
hypoglycemic agents - therapeutic use (858) 858
type 2 diabetes (848) 848
female (777) 777
dipeptidyl-peptidase iv inhibitors - adverse effects (741) 741
endocrinology & metabolism (722) 722
middle aged (665) 665
diabetes (639) 639
hypoglycemic agents - adverse effects (557) 557
aged (542) 542
treatment outcome (485) 485
animals (477) 477
glucagon-like peptide-1 (462) 462
pharmacology & pharmacy (453) 453
sitagliptin (440) 440
diabetes mellitus, type 2 - blood (417) 417
double-blind (389) 389
adamantane - analogs & derivatives (388) 388
adult (384) 384
glucose (375) 375
metformin (371) 371
dipeptidyl-peptidase iv inhibitors - administration & dosage (363) 363
glycemic control (354) 354
hypoglycemic agents (350) 350
dipeptidyl-peptidase iv inhibitors - pharmacology (347) 347
dipeptidyl peptidase-4 inhibitor (344) 344
drug therapy, combination (332) 332
hypoglycemic agents - administration & dosage (319) 319
risk factors (308) 308
blood glucose - drug effects (304) 304
blood glucose - metabolism (298) 298
insulin (287) 287
diabetes mellitus (284) 284
vildagliptin (283) 283
care and treatment (268) 268
dipeptidyl peptidase 4 - metabolism (263) 263
safety (263) 263
metformin - therapeutic use (258) 258
sitagliptin phosphate (255) 255
analysis (254) 254
adamantane - therapeutic use (250) 250
type 2 diabetes mellitus (248) 248
drug therapy (247) 247
type-2 diabetes-mellitus (247) 247
diabetes mellitus, type 2 - complications (242) 242
glycated hemoglobin a - metabolism (239) 239
double-blind method (237) 237
diabetes therapy (236) 236
efficacy (229) 229
dipeptidyl peptidase-4 inhibitors (227) 227
beta-cell function (220) 220
hypoglycemic agents - pharmacology (219) 219
internal medicine (219) 219
medicine, general & internal (214) 214
adamantane - adverse effects (203) 203
dpp-4 inhibitor (202) 202
research (202) 202
clinical trials (196) 196
improves glycemic control (194) 194
dextrose (192) 192
hypoglycemia - chemically induced (188) 188
linagliptin (185) 185
hypoglycemia (180) 180
therapy (180) 180
abridged index medicus (178) 178
mellitus (175) 175
glucagon (174) 174
triazoles - therapeutic use (170) 170
pyrazines - therapeutic use (169) 169
diabetes mellitus, type 2 - metabolism (161) 161
peptidase (161) 161
pyrrolidines - therapeutic use (160) 160
risk (160) 160
sulfonylurea compounds - therapeutic use (160) 160
dosage and administration (156) 156
dpp-4 inhibitors (156) 156
medicine & public health (156) 156
peptides (156) 156
randomized controlled trials as topic (155) 155
nitriles - therapeutic use (153) 153
health aspects (152) 152
rats (152) 152
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (151) 151
hyperglycemia (151) 151
cardiac & cardiovascular systems (146) 146
dipeptidyl-peptidase iv inhibitors (145) 145
glp-1 (144) 144
mice (144) 144
incretins - therapeutic use (143) 143
drug-naive patients (142) 142
pharmacokinetics (142) 142
time factors (139) 139
diabetes mellitus, type 2 - physiopathology (135) 135
saxagliptin (131) 131
glycosylated hemoglobin (129) 129
mortality (128) 128
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2080) 2080
French (18) 18
German (16) 16
Spanish (14) 14
Japanese (7) 7
Hungarian (3) 3
Russian (3) 3
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article